HF
CYTK icon

HRT Financial’s Cytokinetics CYTK Stock Holding History

HRT Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,376
Closed -$1.49M – 3957
2025
Q4 		$1.49M Buy
+23,376
New +$1.45M ﹤0.01% 1487
2024
Q4 		– Sell
-14,049
Closed -$741K – 2562
2024
Q3 		$741K Buy
+14,049
New +$783K ﹤0.01% 1399
2024
Q2 		– Sell
-430,821
Closed -$30.2M – 2375
2024
Q1 		$30.2M Buy
430,821
+387,904
+904% +$30M 0.19% 52
2023
Q4 		$3.58M Buy
+42,917
New +$1.55M 0.03% 417
2023
Q1 		– Sell
-8,292
Closed -$379K – 2607
2022
Q4 		$379K Buy
+8,292
New +$357K 0.01% 1599
2021
Q3 		– Sell
-12,500
Closed -$247K – 3373
2021
Q2 		$247K Buy
+12,500
New +$294K ﹤0.01% 2269

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's CYTK Position: Q1 2026 in Review

HRT Financial sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 23,376 shares — an estimated $1.49M sold.

HRT Financial first reported a position in CYTK in Q2 2021 and held it in 6 quarters. The position peaked at $30.2M in Q1 2024. 440 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • HRT Financial reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 23,376 Cytokinetics shares in Q1 2026, an estimated $1.49M.
  • HRT Financial first reported a position in Cytokinetics in Q2 2021 and held it in 6 quarters.
  • HRT Financial's Cytokinetics position peaked at $30.2M in Q1 2024.
  • 440 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.